神経内分泌がんの世界市場 2020年

• 英文タイトル：Global Neuroendocrine Carcinoma Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：GIR201114648 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医薬品・医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本書では、神経内分泌がんの世界市場を調査対象にし、神経内分泌がんの市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（化学療法、ソマトスタチン類似体、標的療法）、用途別分析（病院、クリニック、腫瘍センター、外来手術センター）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Pfizer、Teva、Ipsen、Novartis、Jubilant、Chiasma、Advanced Accelerator、Valeant、Abbvie、F.Hoffmann-La Roche、Mateon、Lexicon ・企業別売上、市場シェア ・神経内分泌がんの地域別市場分析 ・神経内分泌がんの北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・神経内分泌がんのヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・神経内分泌がんのアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・神経内分泌がんの南米市場規模2015-2020：ブラジル、アルゼンチンなど ・神経内分泌がんの中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・神経内分泌がんの種類別市場規模2015-2020：化学療法、ソマトスタチン類似体、標的療法 ・神経内分泌がんの用途別市場規模2015-2020：病院、クリニック、腫瘍センター、外来手術センター ・神経内分泌がんの世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論

Market Overview
The global Neuroendocrine Carcinoma market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Neuroendocrine Carcinoma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Neuroendocrine Carcinoma market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Neuroendocrine Carcinoma market has been segmented into:
Chemotherapy
Somatostatin Analogs
Targeted Therapy

By Application, Neuroendocrine Carcinoma has been segmented into:
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuroendocrine Carcinoma market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuroendocrine Carcinoma markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuroendocrine Carcinoma market.

The report offers in-depth assessment of the growth and other aspects of the Neuroendocrine Carcinoma market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Neuroendocrine Carcinoma Market Share Analysis
Neuroendocrine Carcinoma competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuroendocrine Carcinoma sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuroendocrine Carcinoma sales, revenue and market share for each player covered in this report.

The major players covered in Neuroendocrine Carcinoma are:
Pfizer
Teva
Ipsen
Novartis
Jubilant
Chiasma
Advanced Accelerator
Valeant
Abbvie
F.Hoffmann-La Roche
Mateon
Lexicon

レポート目次

---

Table of Contents

1 Neuroendocrine Carcinoma Market Overview
1.1 Product Overview and Scope of Neuroendocrine Carcinoma
1.2 Classification of Neuroendocrine Carcinoma by Type
1.2.1 Global Neuroendocrine Carcinoma Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Neuroendocrine Carcinoma Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Somatostatin Analogs
1.2.5 Targeted Therapy
1.3 Global Neuroendocrine Carcinoma Market by Application
1.3.1 Overview: Global Neuroendocrine Carcinoma Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 Global Neuroendocrine Carcinoma Market by Regions
1.4.1 Global Neuroendocrine Carcinoma Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Neuroendocrine Carcinoma (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Neuroendocrine Carcinoma Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Neuroendocrine Carcinoma Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neuroendocrine Carcinoma Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Neuroendocrine Carcinoma Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neuroendocrine Carcinoma Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Teva SWOT Analysis
2.2.4 Teva Product and Services
2.2.5 Teva Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.3 Ipsen
2.3.1 Ipsen Details
2.3.2 Ipsen Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Ipsen SWOT Analysis
2.3.4 Ipsen Product and Services
2.3.5 Ipsen Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.5 Jubilant
2.5.1 Jubilant Details
2.5.2 Jubilant Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Jubilant SWOT Analysis
2.5.4 Jubilant Product and Services
2.5.5 Jubilant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.6 Chiasma
2.6.1 Chiasma Details
2.6.2 Chiasma Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Chiasma SWOT Analysis
2.6.4 Chiasma Product and Services
2.6.5 Chiasma Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.7 Advanced Accelerator
2.7.1 Advanced Accelerator Details
2.7.2 Advanced Accelerator Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Advanced Accelerator SWOT Analysis
2.7.4 Advanced Accelerator Product and Services
2.7.5 Advanced Accelerator Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.8 Valeant
2.8.1 Valeant Details
2.8.2 Valeant Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Valeant SWOT Analysis
2.8.4 Valeant Product and Services
2.8.5 Valeant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.9 Abbvie
2.9.1 Abbvie Details
2.9.2 Abbvie Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Abbvie SWOT Analysis
2.9.4 Abbvie Product and Services
2.9.5 Abbvie Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.10 F.Hoffmann-La Roche
2.10.1 F.Hoffmann-La Roche Details
2.10.2 F.Hoffmann-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 F.Hoffmann-La Roche SWOT Analysis
2.10.4 F.Hoffmann-La Roche Product and Services
2.10.5 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.11 Mateon
2.11.1 Mateon Details
2.11.2 Mateon Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Mateon SWOT Analysis
2.11.4 Mateon Product and Services
2.11.5 Mateon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
2.12 Lexicon
2.12.1 Lexicon Details
2.12.2 Lexicon Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Lexicon SWOT Analysis
2.12.4 Lexicon Product and Services
2.12.5 Lexicon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Neuroendocrine Carcinoma Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Neuroendocrine Carcinoma Players Market Share
3.2.2 Top 10 Neuroendocrine Carcinoma Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Neuroendocrine Carcinoma Revenue and Market Share by Regions
4.2 North America Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
4.3 Europe Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
4.5 South America Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
5 North America Neuroendocrine Carcinoma Revenue by Countries
5.1 North America Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
5.2 USA Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
5.3 Canada Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
5.4 Mexico Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
6 Europe Neuroendocrine Carcinoma Revenue by Countries
6.1 Europe Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
6.2 Germany Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
6.3 UK Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
6.4 France Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
6.5 Russia Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
6.6 Italy Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Neuroendocrine Carcinoma Revenue by Countries
7.1 Asia-Pacific Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
7.2 China Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
7.3 Japan Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
7.4 Korea Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
7.5 India Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
8 South America Neuroendocrine Carcinoma Revenue by Countries
8.1 South America Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
8.2 Brazil Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
8.3 Argentina Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Neuroendocrine Carcinoma by Countries
9.1 Middle East & Africa Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
9.2 Saudi Arabia Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
9.3 UAE Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
9.4 Egypt Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
9.5 South Africa Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Neuroendocrine Carcinoma Revenue and Market Share by Type (2015-2020)
10.2 Global Neuroendocrine Carcinoma Market Forecast by Type (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Somatostatin Analogs Revenue Growth Rate (2015-2025)
10.5 Targeted Therapy Revenue Growth Rate (2015-2025)
11 Global Neuroendocrine Carcinoma Market Segment by Application
11.1 Global Neuroendocrine Carcinoma Revenue Market Share by Application (2015-2020)
11.2 Neuroendocrine Carcinoma Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Oncology Centres Revenue Growth (2015-2020)
11.6 Ambulatory Surgery Centres Revenue Growth (2015-2020)
12 Global Neuroendocrine Carcinoma Market Size Forecast (2021-2025)
12.1 Global Neuroendocrine Carcinoma Market Size Forecast (2021-2025)
12.2 Global Neuroendocrine Carcinoma Market Forecast by Regions (2021-2025)
12.3 North America Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
12.4 Europe Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
12.6 South America Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Neuroendocrine Carcinoma Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuroendocrine Carcinoma by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuroendocrine Carcinoma Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Neuroendocrine Carcinoma Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Neuroendocrine Carcinoma Major Business
Table 7. Pfizer Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Neuroendocrine Carcinoma Product and Solutions
Table 10. Pfizer Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Teva Corporate Information, Location and Competitors
Table 12. Teva Neuroendocrine Carcinoma Major Business
Table 13. Teva Neuroendocrine Carcinoma Total Revenue (USD Million) (2018-2019)
Table 14. Teva SWOT Analysis
Table 15. Teva Neuroendocrine Carcinoma Product and Solutions
Table 16. Teva Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Ipsen Corporate Information, Location and Competitors
Table 18. Ipsen Neuroendocrine Carcinoma Major Business
Table 19. Ipsen Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 20. Ipsen SWOT Analysis
Table 21. Ipsen Neuroendocrine Carcinoma Product and Solutions
Table 22. Ipsen Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Novartis Corporate Information, Location and Competitors
Table 24. Novartis Neuroendocrine Carcinoma Major Business
Table 25. Novartis Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 26. Novartis SWOT Analysis
Table 27. Novartis Neuroendocrine Carcinoma Product and Solutions
Table 28. Novartis Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Jubilant Corporate Information, Location and Competitors
Table 30. Jubilant Neuroendocrine Carcinoma Major Business
Table 31. Jubilant Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 32. Jubilant SWOT Analysis
Table 33. Jubilant Neuroendocrine Carcinoma Product and Solutions
Table 34. Jubilant Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Chiasma Corporate Information, Location and Competitors
Table 36. Chiasma Neuroendocrine Carcinoma Major Business
Table 37. Chiasma Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 38. Chiasma SWOT Analysis
Table 39. Chiasma Neuroendocrine Carcinoma Product and Solutions
Table 40. Chiasma Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Advanced Accelerator Corporate Information, Location and Competitors
Table 42. Advanced Accelerator Neuroendocrine Carcinoma Major Business
Table 43. Advanced Accelerator Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 44. Advanced Accelerator SWOT Analysis
Table 45. Advanced Accelerator Neuroendocrine Carcinoma Product and Solutions
Table 46. Advanced Accelerator Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Valeant Corporate Information, Location and Competitors
Table 48. Valeant Neuroendocrine Carcinoma Major Business
Table 49. Valeant Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 50. Valeant SWOT Analysis
Table 51. Valeant Neuroendocrine Carcinoma Product and Solutions
Table 52. Valeant Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Abbvie Corporate Information, Location and Competitors
Table 54. Abbvie Neuroendocrine Carcinoma Major Business
Table 55. Abbvie Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 56. Abbvie SWOT Analysis
Table 57. Abbvie Neuroendocrine Carcinoma Product and Solutions
Table 58. Abbvie Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. F.Hoffmann-La Roche Corporate Information, Location and Competitors
Table 60. F.Hoffmann-La Roche Neuroendocrine Carcinoma Major Business
Table 61. F.Hoffmann-La Roche Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 62. F.Hoffmann-La Roche SWOT Analysis
Table 63. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product and Solutions
Table 64. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Mateon Corporate Information, Location and Competitors
Table 66. Mateon Neuroendocrine Carcinoma Major Business
Table 67. Mateon Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 68. Mateon SWOT Analysis
Table 69. Mateon Neuroendocrine Carcinoma Product and Solutions
Table 70. Mateon Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Lexicon Corporate Information, Location and Competitors
Table 72. Lexicon Neuroendocrine Carcinoma Major Business
Table 73. Lexicon Neuroendocrine Carcinoma Total Revenue (USD Million) (2017-2018)
Table 74. Lexicon SWOT Analysis
Table 75. Lexicon Neuroendocrine Carcinoma Product and Solutions
Table 76. Lexicon Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Global Neuroendocrine Carcinoma Revenue (Million USD) by Players (2015-2020)
Table 78. Global Neuroendocrine Carcinoma Revenue Share by Players (2015-2020)
Table 79. Global Neuroendocrine Carcinoma Revenue (Million USD) by Regions (2015-2020)
Table 80. Global Neuroendocrine Carcinoma Revenue Market Share by Regions (2015-2020)
Table 81. North America Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
Table 82. North America Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Table 83. Europe Neuroendocrine Carcinoma Revenue (Million USD) by Countries (2015-2020)
Table 84. Asia-Pacific Neuroendocrine Carcinoma Revenue (Million USD) by Countries (2015-2020)
Table 85. South America Neuroendocrine Carcinoma Revenue by Countries (2015-2020)
Table 86. South America Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Table 87. Middle East and Africa Neuroendocrine Carcinoma Revenue (Million USD) by Countries (2015-2020)
Table 88. Middle East and Africa Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Table 89. Global Neuroendocrine Carcinoma Revenue (Million USD) by Type (2015-2020)
Table 90. Global Neuroendocrine Carcinoma Revenue Share by Type (2015-2020)
Table 91. Global Neuroendocrine Carcinoma Revenue Forecast by Type (2021-2025)
Table 92. Global Neuroendocrine Carcinoma Revenue by Application (2015-2020)
Table 93. Global Neuroendocrine Carcinoma Revenue Share by Application (2015-2020)
Table 94. Global Neuroendocrine Carcinoma Revenue Forecast by Application (2021-2025)
Table 95. Global Neuroendocrine Carcinoma Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Neuroendocrine Carcinoma Picture
Figure 2. Global Neuroendocrine Carcinoma Revenue Market Share by Type in 2019
Figure 3. Chemotherapy Picture
Figure 4. Somatostatin Analogs Picture
Figure 5. Targeted Therapy Picture
Figure 6. Neuroendocrine Carcinoma Revenue Market Share by Application in 2019
Figure 7. Hospital Picture
Figure 8. Clinics Picture
Figure 9. Oncology Centres Picture
Figure 10. Ambulatory Surgery Centres Picture
Figure 11. Global Neuroendocrine Carcinoma Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Neuroendocrine Carcinoma Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Neuroendocrine Carcinoma Revenue Market Share in 2019
Figure 20. Global Top 10 Players Neuroendocrine Carcinoma Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Neuroendocrine Carcinoma Revenue Market Share by Regions (2015-2020)
Figure 24. Global Neuroendocrine Carcinoma Revenue Market Share by Regions in 2018
Figure 25. North America Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 26. Europe Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 28. South America Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 30. North America Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Figure 31. North America Neuroendocrine Carcinoma Revenue Market Share by Countries in 2019
Figure 32. USA Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 33. Canada Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 35. Europe Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Neuroendocrine Carcinoma Revenue Market Share by Countries in 2019
Figure 37. Germany Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 38. UK Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 39. France Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 40. Russia Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 41. Italy Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Neuroendocrine Carcinoma Revenue Market Share by Countries in 2019
Figure 44. China Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 45. Japan Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 46. Korea Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 47. India Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 49. South America Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Figure 50. South America Neuroendocrine Carcinoma Revenue Market Share by Countries in 2019
Figure 51. Brazil Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Neuroendocrine Carcinoma Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Neuroendocrine Carcinoma Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 56. UAE Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Neuroendocrine Carcinoma Revenue and Growth Rate (2015-2020)
Figure 59. Global Neuroendocrine Carcinoma Revenue Share by Type (2015-2020)
Figure 60. Global Neuroendocrine Carcinoma Revenue Share by Type in 2019
Figure 61. Global Neuroendocrine Carcinoma Market Share Forecast by Type (2021-2025)
Figure 62. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 63. Global Somatostatin Analogs Revenue Growth Rate (2015-2020)
Figure 64. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 65. Global Neuroendocrine Carcinoma Revenue Share by Application (2015-2020)
Figure 66. Global Neuroendocrine Carcinoma Revenue Share by Application in 2019
Figure 67. Global Neuroendocrine Carcinoma Market Share Forecast by Application (2021-2025)
Figure 68. Global Hospital Revenue Growth Rate (2015-2020)
Figure 69. Global Clinics Revenue Growth Rate (2015-2020)
Figure 70. Global Oncology Centres Revenue Growth Rate (2015-2020)
Figure 71. Global Ambulatory Surgery Centres Revenue Growth Rate (2015-2020)
Figure 72. Global Neuroendocrine Carcinoma Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Neuroendocrine Carcinoma Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Neuroendocrine Carcinoma Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
Figure 76. Europe Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
Figure 78. South America Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Neuroendocrine Carcinoma Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel

---